MRD Analytical Validation Working Group
Jimmy Lin, MD, PhD
Chief Scientific Officer
Freenome
Co-Chairs
Mark Sausen, PhD
Senior Director, Precision Medicine Search, Evaluation & Alliances
Bristol Myers Squibb
Current Projects
MRD Tumor-Informed AV Protocols (manuscript in peer review, group is no longer meeting)
MRD Tumor-Agnostic AV Protocols (FDA pre-submission in preparation)
Participating Organizations
Adela, Association for Molecular Pathology (AMP), AstraZeneca, Bristol Myers Squibb (BMS), Delfi Diagnostics, Exact Sciences, Foundation Medicine, Freenome, Grail, Guardant Health, Horizon Discovery, Illumina, Labcorp, LGC SeraCare, Memorial Sloan Kettering Cancer Center (MSKCC), Meridian Life Sciences, Natera, NeoGenomics, Pfizer, Roche Diagnostics, Tempus, Ultima Genomics, Veracyte
Past Deliverables
Not applicable at this time.
Meetings
This working group meets on zoom every other Thursday from 3:30 PM - 5:00 PM EST.
Special workshops and sessions:
Not applicable at this time.

